What do systematic reviews say?

Neonatal vitamin A supplementation vs control

Neonatal vitamin A supplementation leads to higher adverse events during first 48‐72 hours post supplementation ‐… compared with control (high certainty).

• Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle… 2017 · Cochrane Headline outcomes only
  RR 1.53 [1.11, 2.11]
  5 studies · 100256 participants
  High

Neonatal vitamin A supplementation vs control

Neonatal vitamin A supplementation showed no clear difference in adverse events during first 48‐72 hours post supplementation ‐… compared with control (high certainty).

• Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle… 2017 · Cochrane Headline outcomes only
  RR 1 [0.93, 1.07]
  5 studies · 99582 participants
  High

Neonatal vitamin A supplementation vs control

Neonatal vitamin A supplementation showed no clear difference in adverse events during first 48‐72 hours post supplementation ‐… compared with control (low certainty).

• Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle… 2017 · Cochrane Headline outcomes only
  RR 0.96 [0.81, 1.13]
  5 studies · 102638 participants
  Low

Multivitamin plus iron plus folate vs iron plus folate

The review found no eligible studies for this question.

• Vitamin supplementation for preventing miscarriage 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Staple foods fortified with vitamin A vs same unfortified staple foods

• Fortification of staple foods with vitamin A for vitamin A deficiency 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1829 participants
  Very low

Staple foods fortified with vitamin A vs same unfortified staple foods

The review found no eligible studies for this question.

• Fortification of staple foods with vitamin A for vitamin A deficiency 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Staple foods fortified with vitamin A vs same unfortified staple foods

The review found no eligible studies for this question.

• Fortification of staple foods with vitamin A for vitamin A deficiency 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin K antagonists vs placebo or no thromboprophylaxis

Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.15 [0.02, 1.2]
  1 study · 311 participants
  Low

Vitamin K antagonists vs placebo or no thromboprophylaxis

Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 3.82 [0.97, 15.04]
  4 studies · 994 participants
  Low

Vitamin K antagonists vs placebo or no thromboprophylaxis

It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.05 [0.07, 16.58]
  1 study · 311 participants
  Very low

Vitamin K antagonists vs placebo or no thromboprophylaxis

Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.08 [0, 1.42]
  1 study · 311 participants
  Low

Vitamin K antagonists vs placebo or no thromboprophylaxis

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin K antagonists vs placebo or no thromboprophylaxis

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin K antagonists vs placebo or no thromboprophylaxis

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin K antagonists vs active control

Vitamin K antagonists showed no clear difference in symptomatic VTE compared with active control (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.5 [0.74, 3.04]
  1 study · 440 participants
  Moderate

Vitamin K antagonists vs active control

Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 0.14 [0.01, 2.75]
  1 study · 440 participants
  Low

Vitamin K antagonists vs active control

Vitamin K antagonists showed no clear difference in symptomatic PE compared with active control (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1 [0.25, 3.95]
  1 study · 440 participants
  Moderate

Vitamin K antagonists vs active control

Vitamin K antagonists showed no clear difference in symptomatic DVT compared with active control (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.75 [0.75, 4.09]
  1 study · 440 participants
  Moderate

Vitamin K antagonists vs active control

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin K antagonists vs active control

The review found no eligible studies for this question.

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found